NCT05298085View on ClinicalTrials.gov

Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

April 11, 2023

Study Completion Date

April 11, 2023

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Oxytocin nasal spray

Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study

DRUG

Placebo

Study treatment will be administered intranasally daily for 12 weeks.

Trial Locations (4)

Unknown

Hopital Jeanne de Flandre, Lille

Hôpital Femme-Mère-enfant Groupement hospitalier Est, Lyon

Chu Rouen, Rouen

CHU de Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER